Novel progression on clinical therapy of COVID-19: Western and Traditional Chinese Medicines

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus that causes a global epidemic named COVID-19. It still continues to plague humans with severe complications and unique sequelae, causing huge economic losses in the world. Pathophysiological studies showed that important life organs, such as the lungs, brain, kidneys, heart, liver, and immune system, and even reproductive ones are affected directly or indirectly in patients with COVID-19. Classically and newly discovered drugs, concerning antiviral replication, anti-inflammation, blockage of pathogenic processes, alleviation of symptoms, and especially distinctive multi-actions of Traditional Chinese Medicine, were screened out and tested, presenting promising therapeutic effects on the virus before or even though abundant effective vaccines come out. Moreover, other strategies are underway, including the use of plasma therapy, monoclonal neutralizing antibodies, vaccine trials, and emerging drugs with distinct interference mechanisms. This review features the novel progress on the latest-discovered antiviral drugs and the effective Traditional Chinese Medicine, and highlights the advantages and shortages of different therapeutic strategies and the predicted potential targets of the used Traditional Chinese Medicine components, which provides a valuable reference for clinical treatment continuously to combat COVID-19.

Keywords

COVID-19 / Western medicine / Traditional Chinese Medicine / therapeutic effect / adverse action / target molecule

References

[1] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395: 497-506.

[2] Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus—Infected Pneumonia in Wuhan, China. JAMA. 2020; 323: 1061—9.

[3] Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 Cases With Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis. 2020; 71: 769-77.

[4] Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395: 507—13.

[5] Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, et al. Clinical characteristics of COVID—19—infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020; 31: 894-901.

[6] Song F, Shi N, Shan F, Zhang Z, Shen J, Lu H, et al. Emerging 2019 Novel Coronavirus (2019—nCoV) Pneumonia. Radiology. 2020; 295: 210-7.

[7] Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person—to—person transmission: a study of a family cluster. Lancet. 2020; 395: 514—23.

[8] Mao B, Liu Y, Chai YH, Jin XY, Lu HW, Yang JW, et al. Assessing risk factors for SARS—CoV—2 infection in patients presenting with symptoms in Shanghai, China: a multicentre, observational cohort study. Lancet Digit Health. 2020; 2: e323-30.

[9] Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 6) [Internet]. [cited 2020 Feb 29]. Available from: http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2/files/b218cfeb1bc54639af227f922bf6b817.pdf

[10] Coronavirus disease (COVID—19) Epidemiological Updates and Monthly Operational Updates [Internet]. WHO; c2025 [cited 2022 Jun 22]. Available from: https://www.who.int/emergencies/diseases/novel—coronavirus—2019/situation—reports

[11] Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579: 270—3.

[12] Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395: 565-74.

[13] Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome—related coronavirus: classifying 2019—nCoV and naming it SARS—CoV—2. Nat Microbiol. 2020; 5: 536-44.

[14] Burkard C, Verheije MH, Wicht O, van Kasteren SI, van Kuppeveld FJ, Haagmans BL, et al. Coronavirus cell entry occurs through the endo—/lysosomal pathway in a proteolysis—dependent manner. PLoS Pathog. 2014; 10: e1004502.

[15] Delmas B, Laude H. Assembly of coronavirus spike protein into trimers and its role in epitope expression. J Virol. 1990; 64: 5367—75.

[16] Beniac DR, Andonov A, Grudeski E, Booth TF. Architecture of the SARS coronavirus prefusion spike. Nat Struct Mol Biol. 2006; 13: 751—2.

[17] Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005; 2: 69.

[18] Hoffmann M, Kleine—Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS—CoV—2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020; 181: 271-80.e8.

[19] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID—19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395: 1054-62.

[20] Peersen OB. A Comprehensive Superposition of Viral Polymerase Structures. Viruses. 2019; 11: 745.

[21] Cannalire R, Cerchia C, Beccari AR, Di Leva FS, Summa V. Targeting SARS—CoV—2 Proteases and Polymerase for COVID—19 Treatment: State of the Art and Future Opportunities. J Med Chem. 2022; 65: 2716-46.

[22] Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, et al. Crystal structure of SARS—CoV—2 main protease provides a basis for design of improved α—ketoamide inhibitors. Science. 2020; 368: 409—12.

[23] Wang BX, Fish EN. Global virus outbreaks: Interferons as 1st responders. Semin Immunol. 2019; 43: 101300.

[24] de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016; 14: 523—34.

[25] Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, et al. Therapeutic efficacy of the small molecule GS—5734 against Ebola virus in rhesus monkeys. Nature. 2016; 531: 381—5.

[26] Zhang L, Zhou R. Structural Basis of the Potential Binding Mechanism of Remdesivir to SARS—CoV—2 RNA—Dependent RNA Polymerase. J Phys Chem B. 2020; 124: 6955-62.

[27] Chang YC, Tung YA, Lee KH, Chen TF, Hsiao YC, Chang HC, et al. Potential Therapeutic Agents for COVID—19 Based on the Analysis of Protease and RNA Polymerase Docking. 2020020242 [Preprint]. 2020 [cited 2022 Mar 21]: [11 p.]. Available from: https://www.preprints.org/manuscript/202002.0242

[28] Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019—nCoV) in vitro. Cell Res. 2020; 30: 269-71.

[29] Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate Use of Remdesivir for Patients with Severe Covid—19. N Engl J Med. 2020; 382: 2327—36.

[30] Gilead Announces Results From Phase 3 Trial of Investigational Antiviral Remdesivir in Patients With Severe COVID—19 [Internet]. Gilead Sciences, Inc.; c1996— 2025 [cited 2022 Mar 21]. Available from: https://www.gilead.com/news—and—press/press—room/press—releases/2020/4/gilead—announces—results—from—phase—3—trial—of—investigational—antiviral—remdesivir—in—patients—with—severe—covid—19

[31] Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID—19: a randomised, double—blind, placebo—controlled, multicentre trial. Lancet. 2020; 395: 1569-78.

[32] Pruijssers AJ, Denison MR. Nucleoside analogues for the treatment of coronavirus infections. Curr Opin Virol. 2019; 35: 57-62.

[33] Sheahan TP, Sims AC, Zhou S, Graham RL, Pruijssers AJ, Agostini ML, et al. An orally bioavailable broad—spectrum antiviral inhibits SARS—CoV—2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020; 12: eabb5883.

[34] Gordon CJ, Tchesnokov EP, Schinazi RF, Götte M. Molnupiravir promotes SARS—CoV—2 mutagenesis via the RNA template. J Biol Chem. 2021; 297: 100770.

[35] Rosenke K, Hansen F, Schwarz B, Feldmann F, Haddock E, Rosenke R, et al. Orally delivered MK—4482 inhibits SARS—CoV—2 replication in the Syrian hamster model. Nat Commun. 2021; 12: 2295.

[36] Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, et al. ; Coalition Covid—19 Brazil I Investigators. Hydroxychloroquine with or without Azithromycin in Mild—to—Moderate Covid—19. N Engl J Med. 2020; 383: 2041-52.

[37] Wahl A, Gralinski LE, Johnson CE, Yao W, Kovarova M, Dinnon KH 3rd, et al. SARS—CoV—2 infection is effectively treated and prevented by EIDD—2801. Nature. 2021; 591: 451-7.

[38] Cox RM, Wolf JD, Plemper RK. Therapeutically administered ribonucleoside analogue MK—4482/EIDD—2801 blocks SARS—CoV—2 transmission in ferrets. Nat Microbiol. 2021; 6: 11-8.

[39] Mahase E. Covid—19: Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports. BMJ. 2021; 375: n2422.

[40] Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID—19 in Positive Interim Analysis of Phase 3 Study [Internet]. Rahway: Merck & Co., Inc.; c2025 [cited 2021 Oct 1]. Available from: https://www.merck.com/news/merck—and—ridgebacks—investigational—oral—antiviral—molnupiravir—reduced—the—risk—of—hospitalization—or—death—by—approximately—50—percent—compared—to—placebo—for—patients—with—mild—or—moderat/

[41] Kabinger F, Stiller C, Schmitzová J, Dienemann C, Kokic G, Hillen HS, et al. Mechanism of molnupiravir—induced SARS—CoV—2 mutagenesis. Nat Struct Mol Biol. 2021; 28: 740-6.

[42] Menéndez—Arias L. Decoding molnupiravir—induced mutagenesis in SARS—CoV—2. J Biol Chem. 2021; 297: 100867.

[43] Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK. Broad—spectrum antiviral activity of Virazole: 1—β—D—ribofuranosyl—1,2,4—triazole—3—carboxamide. Science. 1972; 177: 705-6.

[44] Knowles SR, Phillips EJ, Dresser L, Matukas L. Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada. Clin Infect Dis. 2003; 37: 1139—42.

[45] Todt D, Friesland M, Moeller N, Praditya D, Kinast V, Brüggemann Y, et al. Robust hepatitis E virus infection and transcriptional response in human hepatocytes. Proc Natl Acad Sci U S A. 2020; 117: 1731-41.

[46] Marion O, Lhomme S, Nayrac M, Dubois M, Pucelle M, Requena M, et al. Hepatitis E virus replication in human intestinal cells. Gut. 2020; 69: 901-10.

[47] Nam HH, Ison MG. Respiratory syncytial virus infection in adults. BMJ. 2019; 366: l5021.

[48] Lok AS, Sulkowski MS, Kort JJ, Willner I, Reddy KR, Shiffman ML, et al. Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy. Gastroenterology. 2019; 157: 1506—17.e1.

[49] Sidwell RW, Robins RK, Hillyard IW. Ribavirin: an antiviral agent. Pharmacol Ther. 1979; 6: 123—46.

[50] Xu X, Liu Y, Weiss S, Arnold E, Sarafianos SG, Ding J. Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug design. Nucleic Acids Res. 2003; 31: 7117—30.

[51] Elfiky AA. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS—CoV—2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci. 2020; 253: 117592.

[52] Peiris JS, Chu CM, Cheng VC, Chan KS, Hung IF, Poon LL, et al. ; HKU/UCH SARS Study Group. Clinical progression and viral load in a community outbreak of coronavirus—associated SARS pneumonia: a prospective study. Lancet. 2003; 361: 1767—72.

[53] Tsang KW, Lam WK. Management of severe acute respiratory syndrome: the Hong Kong University experience. Am J Respir Crit Care Med. 2003; 168: 417—24.

[54] Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7) [Internet]. National Health Commission of the People’s Republic of China; [cited 2020 Mar 4]. Available from: http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml

[55] Hung IF, Lung KC, Tso EY, Liu R, Chung TW, Chu MY, et al. Triple combination of interferon beta—1b, lopinavir—ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID—19: an open—label, randomised, phase 2 trial. Lancet. 2020; 395: 1695-704.

[56] Abbaspour Kasgari H, Moradi S, Shabani AM, Babamahmoodi F, Davoudi Badabi AR, Davoudi L, et al. Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID—19 patients with moderate disease compared with standard care: a single—centre, randomized controlled trial. J Antimicrob Chemother. 2020; 75: 3373—8.

[57] Tong S, Su Y, Yu Y, Wu C, Chen J, Wang S, et al. Ribavirin therapy for severe COVID—19: a retrospective cohort study. Int J Antimicrob Agents. 2020; 56: 106114.

[58] Eslami G, Mousaviasl S, Radmanesh E, Jelvay S, Bitaraf S, Simmons B, et al. The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID—19. J Antimicrob Chemother. 2020; 75: 3366—72.

[59] Heo YA, Deeks ED. Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C. Drugs. 2018; 78: 577-87.

[60] Tian L, Qiang T, Liang C, Ren X, Jia M, Zhang J, et al. RNA—dependent RNA polymerase (RdRp) inhibitors: The current landscape and repurposing for the COVID—19 pandemic. Eur J Med Chem. 2021; 213: 113201.

[61] Zein AFMZ, Sulistiyana CS, Raffaello WM, Wibowo A, Pranata R. Sofosbuvir with daclatasvir and the outcomes of patients with COVID—19: a systematic review and meta—analysis with GRADE assessment. Postgrad Med J. 2022; 98: 509-14.

[62] Sadeghi A, Ali Asgari A, Norouzi A, Kheiri Z, Anushirvani A, Montazeri M, et al. Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID—19): a randomized controlled trial. J Antimicrob Chemother. 2020; 75: 3379-85.

[63] Simmons B, Wentzel H, Mobarak S, Eslami G, Sadeghi A, Ali Asgari A, et al. Sofosbuvir/daclatasvir regimens for the treatment of COVID—19: an individual patient data meta—analysis. J Antimicrob Chemother. 2021; 76: 286-91.

[64] Hoffman RL, Kania RS, Brothers MA, Davies JF, Ferre RA, Gajiwala KS, et al. Discovery of Ketone—Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID—19. J Med Chem. 2020; 63: 12725—47.

[65] Owen DR, Allerton CMN, Anderson AS, Aschenbrenner L, Avery M, Berritt S, et al. An oral SARS—CoV—2 M^pro inhibitor clinical candidate for the treatment of COVID—19. Science. 2021; 374: 1586-93.

[66] Mahase E. Covid—19: Pfizer’s paxlovid is 89% effective in patients at risk of serious illness, company reports. BMJ. 2021; 375: n2713.

[67] Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs. 2003; 63: 769-802.

[68] Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, et al. ; HKU/UCH SARS Study Group. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004; 59: 252—6.

[69] Chan KS, Lai ST, Chu CM, Tsui E, Tam CY, Wong MM, et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J. 2003; 9: 399-406.

[70] de Wilde AH, Jochmans D, Posthuma CC, Zevenhoven—Dobbe JC, van Nieuwkoop S, Bestebroer TM, et al. Screening of an FDA—approved compound library identifies four small—molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother. 2014; 58: 4875-84.

[71] Chan JF, Yao Y, Yeung ML, Deng W, Bao L, Jia L, et al. Treatment With Lopinavir/Ritonavir or Interferon—β1b Improves Outcome of MERS—CoV Infection in a Nonhuman Primate Model of Common Marmoset. J Infect Dis. 2015; 212: 1904—13.

[72] Nukoolkarn V, Lee VS, Malaisree M, Aruksakulwong O, Hannongbua S. Molecular dynamic simulations analysis of ritonavir and lopinavir as SARS—CoV 3CL^pro inhibitors. J Theor Biol. 2008; 254: 861-7.

[73] Kim JY, Choe PG, Oh Y, Oh KJ, Kim J, Park SJ, et al. The First Case of 2019 Novel Coronavirus Pneumonia Imported into Korea from Wuhan, China: Implication for Infection Prevention and Control Measures. J Korean Med Sci. 2020; 35: e61.

[74] Ye XT, Luo YL, Xia SC, Sun QF, Ding JG, Zhou Y, et al. Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019. Eur Rev Med Pharmacol Sci. 2020; 24: 3390—6.

[75] Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ, et al. Case of the Index Patient Who Caused Tertiary Transmission of COVID—19 Infection in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID—19 Infected Pneumonia Monitored by Quantitative RT—PCR. J Korean Med Sci. 2020; 35: e79.

[76] Ngo ST, Quynh Anh Pham N, Thi Le L, Pham DH, Vu VV. Computational Determination of Potential Inhibitors of SARS—CoV—2 Main Protease. J Chem Inf Model. 2020; 60: 5771-80.

[77] Kim EJ, Choi SH, Park JS, Kwon YS, Lee J, Kim Y, et al. Use of Darunavir—Cobicistat as a Treatment Option for Critically Ill Patients with SARS—CoV—2 Infection. Yonsei Med J. 2020; 61: 826—30.

[78] Riva A, Conti F, Bernacchia D, Pezzati L, Sollima S, Merli S, et al. Darunavir does not prevent SARS—CoV—2 infection in HIV patients. Pharmacol Res. 2020; 157: 104826.

[79] Nicolini LA, Mikulska M, Signori A, Di Biagio A, Portunato F, Vena A, et al. Reply to: “Antiviral Activity and Safety of Darunavir/Cobicistat for Treatment of COVID—19”. Open Forum Infect Dis. 2020; 7: ofaa321.

[80] Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, et al. Structure of M^pro from SARS—CoV—2 and discovery of its inhibitors. Nature. 2020; 582: 289-93.

[81] Menéndez CA, Byléhn F, Perez—Lemus GR, Alvarado W, de Pablo JJ. Molecular characterization of ebselen binding activity to SARS—CoV—2 main protease. Sci Adv. 2020; 6: eabd0345.

[82] Schneider WM, Chevillotte MD, Rice CM. Interferon—stimulated genes: a complex web of host defenses. Annu Rev Immunol. 2014; 32: 513—45.

[83] Mantlo E, Bukreyeva N, Maruyama J, Paessler S, Huang C. Antiviral activities of type I interferons to SARS—CoV—2 infection. Antiviral Res. 2020; 179: 104811.

[84] Haagmans BL, Osterhaus AD. Coronaviruses and their therapy. Antiviral Res. 2006; 71: 397-403.

[85] Wang B, Li D, Liu T, Wang H, Luo F, Liu Y. Subcutaneous injection of IFN alpha—2b for COVID—19: an observational study. BMC Infect Dis. 2020; 20: 723.

[86] Adcock IM, Nasuhara Y, Stevens DA, Barnes PJ. Ligand—induced differentiation of glucocorticoid receptor (GR) trans—repression and transactivation: preferential targetting of NF—κB and lack of I—κB involvement. Br J Pharmacol. 1999; 127: 1003-11.

[87] Xavier AM, Anunciato AK, Rosenstock TR, Glezer I. Gene Expression Control by Glucocorticoid Receptors during Innate Immune Responses. Front Endocrinol (Lausanne). 2016; 7: 31.

[88] Escoter—Torres L, Caratti G, Mechtidou A, Tuckermann J, Uhlenhaut NH, Vettorazzi S. Fighting the Fire: Mechanisms of Inflammatory Gene Regulation by the Glucocorticoid Receptor. Front Immunol. 2019; 10: 1859.

[89] Confalonieri M, Cifaldi R, Dreas L, Viviani M, Biolo M, Gabrielli M. Methylprednisolone infusion for life—threatening H1N1—virus infection. Ther Adv Respir Dis. 2010; 4: 233-7.

[90] Roberts C, Nirmalan M, O’Shea S. Steroid—sensitive post—viral inflammatory pneumonitis (PVIP). Am J Respir Crit Care Med. 2010; 182: 1089-90.

[91] Kil HR, Lee JH, Lee KY, Rhim JW, Youn YS, Kang JH. Early corticosteroid treatment for severe pneumonia caused by 2009 H1N1 influenza virus. Crit Care. 2011; 15: 413.

[92] Sung JJ, Wu A, Joynt GM, Yuen KY, Lee N, Chan PK, et al. Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak. Thorax. 2004; 59: 414-20.

[93] Chen RC, Tang XP, Tan SY, Liang BL, Wan ZY, Fang JQ, et al. Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience. Chest. 2006; 129: 1441—52.

[94] Wang Y, Jiang W, He Q, Wang C, Wang B, Zhou P, et al. A retrospective cohort study of methylprednisolone therapy in severe patients with COVID—19 pneumonia. Signal Transduct Target Ther. 2020; 5: 57.

[95] Fang X, Zhao M, Li S, Yang L, Wu B. Changes of CT findings in a 2019 novel coronavirus (2019—nCoV) pneumonia patient. QJM. 2020; 113: 271—2.

[96] Zhou W, Liu Y, Tian D, Wang C, Wang S, Cheng J, et al. Potential benefits of precise corticosteroids therapy for severe 2019—nCoV pneumonia. Signal Transduct Target Ther. 2020; 5: 18.

[97] Xiong Y, Song S, Ye G, Wang X. Family cluster of three recovered cases of pneumonia due to severe acute respiratory syndrome coronavirus 2 infection. BMJ Case Rep. 2020; 13: e235302.

[98] RECOVERY Collaborative Group; Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in Hospitalized Patients with Covid—19. N Engl J Med. 2021; 384: 693-704.

[99] Hassan ME, Hasan HM, Sridharan K, Elkady A, ElSeirafi MM. Dexamethasone in severe COVID—19 infection: A case series. Respir Med Case Rep. 2020; 31: 101205.

[100] WHO Rapid Evidence Appraisal for COVID—19 Therapies (REACT) Working Group; Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, et al. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID—19: A Meta—analysis. JAMA. 2020; 324: 1330—41.

[101] Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019—nCoV lung injury. Lancet. 2020; 395: 473—5.

[102] Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C—reactive protein. N Engl J Med. 2008; 359: 2195-207.

[103] Russo V, Silverio A, Scudiero F, Attena E, D’Andrea A, Nunziata L, et al. Preadmission Statin Therapy and Clinical Outcome in Hospitalized Patients With COVID—19: An Italian Multicenter Observational Study. J Cardiovasc Pharmacol. 2021; 78: e94-100.

[104] Zein AFMZ, Sulistiyana CS, Khasanah U, Wibowo A, Lim MA, Pranata R. Statin and mortality in COVID—19: a systematic review and meta—analysis of pooled adjusted effect estimates from propensity—matched cohorts. Postgrad Med J. 2022; 98: 503—8.

[105] Vitiello A, Ferrara F. Plausible Positive Effects of Statins in COVID—19 Patient. Cardiovasc Toxicol. 2021; 21: 781—9.

[106] Lohia P, Kapur S, Benjaram S, Cantor Z, Mahabadi N, Mir T, et al. Statins and clinical outcomes in hospitalized COVID—19 patients with and without Diabetes Mellitus: a retrospective cohort study with propensity score matching. Cardiovasc Diabetol. 2021; 20: 140.

[107] Madrid RRM, Mathews PD, Patta ACMF, Gonzales—Flores AP, Ramirez CAB, Rigoni VLS, et al. Safety of oral administration of high doses of ivermectin by means of biocompatible polyelectrolytes formulation. Heliyon. 2021; 7: e05820.

[108] Kory P, Meduri GU, Varon J, Iglesias J, Marik PE. Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID—19. Am J Ther. 2021; 28: e299-318.

[109] Bryant A, Lawrie TA, Dowswell T, Fordham EJ, Mitchell S, Hill SR, et al. Ivermectin for Prevention and Treatment of COVID—19 Infection: A Systematic Review, Meta—analysis, and Trial Sequential Analysis to Inform Clinical Guidelines. Am J Ther. 2021; 28: e434-60.

[110] Vallejos J, Zoni R, Bangher M, Villamandos S, Bobadilla A, Plano F, et al. Ivermectin to prevent hospitalizations in patients with COVID—19 (IVERCOR—COVID19) a randomized, double—blind, placebo—controlled trial. BMC Infect Dis. 2021; 21: 635.

[111] de Melo GD, Lazarini F, Larrous F, Feige L, Kornobis E, Levallois S, et al. Attenuation of clinical and immunological outcomes during SARS—CoV—2 infection by ivermectin. EMBO Mol Med. 2021; 13: e14122.

[112] Rajter JC, Sherman MS, Fatteh N, Vogel F, Sacks J, Rajter JJ. Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The Ivermectin in COVID Nineteen Study. Chest. 2021; 159: 85-92.

[113] Hellwig MD, Maia A. A COVID—19 prophylaxis? Lower incidence associated with prophylactic administration of ivermectin. Int J Antimicrob Agents. 2021; 57: 106248.

[114] Nishimoto N, Kishimoto T, Yoshizaki K. Anti—interleukin 6 receptor antibody treatment in rheumatic disease. Ann Rheum Dis. 2000; 59: i21-7.

[115] Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, et al. FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell—Induced Severe or Life—Threatening Cytokine Release Syndrome. Oncologist. 2018; 23: 943-7.

[116] Toniati P, Piva S, Cattalini M, Garrafa E, Regola F, Castelli F, et al. Tocilizumab for the treatment of severe COVID—19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmun Rev. 2020; 19: 102568.

[117] Alattar R, Ibrahim TBH, Shaar SH, Abdalla S, Shukri K, Daghfal JN, et al. Tocilizumab for the treatment of severe coronavirus disease 2019. J Med Virol. 2020; 92: 2042—9.

[118] Coyle J, Igbinomwanhia E, Sanchez—Nadales A, Danciu S, Chu C, Shah N. A Recovered Case of COVID—19 Myocarditis and ARDS Treated With Corticosteroids, Tocilizumab, and Experimental AT—001. JACC Case Rep. 2020; 2: 1331-6.

[119] Mazzitelli M, Arrighi E, Serapide F, Pelle MC, Tassone B, Lionello R, et al. Use of subcutaneous tocilizumab in patients with COVID—19 pneumonia. J Med Virol. 2021; 93: 32-4.

[120] Odièvre MH, de Marcellus C, Ducou Le Pointe H, Allali S, Romain AS, Youn J, et al. Dramatic improvement after tocilizumab of severe COVID—19 in a child with sickle cell disease and acute chest syndrome. Am J Hematol. 2020; 95: E192—4.

[121] Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID—19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020; 117: 10970-5.

[122] Di Giambenedetto S, Ciccullo A, Borghetti A, Gambassi G, Landi F, Visconti E, et al. Off—label use of tocilizumab in patients with SARS—CoV—2 infection. J Med Virol. 2020; 92: 1787—8.

[123] Cellina M, Orsi M, Bombaci F, Sala M, Marino P, Oliva G. Favorable changes of CT findings in a patient with COVID—19 pneumonia after treatment with tocilizumab. Diagn Interv Imaging. 2020; 101: 323—4.

[124] Klopfenstein T, Zayet S, Lohse A, Balblanc JC, Badie J, Royer PY, et al. ; HNF Hospital Tocilizumab multidisciplinary team. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID—19 patients. Med Mal Infect. 2020; 50: 397-400.

[125] Fontana F, Alfano G, Mori G, Amurri A, Tei L, Ballestri M, et al. COVID—19 pneumonia in a kidney transplant recipient successfully treated with tocilizumab and hydroxychloroquine. Am J Transplant. 2020; 20: 1902—6.

[126] Antinori S, Bonazzetti C, Gubertini G, Capetti A, Pagani C, Morena V, et al. Tocilizumab for cytokine storm syndrome in COVID—19 pneumonia: an increased risk for candidemia? Autoimmun Rev. 2020; 19: 102564.

[127] Ghosn L, Chaimani A, Evrenoglou T, Davidson M, Graña C, Schmucker C, et al. Interleukin—6 blocking agents for treating COVID—19: a living systematic review. Cochrane Database Syst Rev. 2021: CD013881.

[128] Della—Torre E, Campochiaro C, Cavalli G, De Luca G, Napolitano A, La Marca S, et al. ; SARI—RAF Study Group; SARI—RAF Study Group members. Interleukin—6 blockade with sarilumab in severe COVID—19 pneumonia with systemic hyperinflammation: an open—label cohort study. Ann Rheum Dis. 2020; 79: 1277-85.

[129] Montesarchio V, Parrela R, Iommelli C, Bianco A, Manzillo E, Fraganza F, et al. Outcomes and biomarker analyses among patients with COVID—19 treated with interleukin 6 (IL—6) receptor antagonist sarilumab at a single institution in Italy. J Immunother Cancer. 2020; 8: e001089.

[130] REMAP—CAP Investigators; Gordon AC, Mouncey PR, Al—Beidh F, Rowan KM, Nichol AD, Arabi YM, et al. Interleukin—6 Receptor Antagonists in Critically Ill Patients with Covid—19. N Engl J Med. 2021; 384: 1491-502.

[131] Gritti G, Raimondi F, Bottazzi B, Ripamonti D, Riva I, Landi F, et al. Siltuximab downregulates interleukin—8 and pentraxin 3 to improve ventilatory status and survival in severe COVID—19. Leukemia. 2021; 35: 2710—4.

[132] Ramírez J, Cañete JD. Anakinra for the treatment of rheumatoid arthritis: a safety evaluation. Expert Opin Drug Saf. 2018; 17: 727—32.

[133] Aouba A, Baldolli A, Geffray L, Verdon R, Bergot E, Martin—Silva N, et al. Targeting the inflammatory cascade with anakinra in moderate to severe COVID—19 pneumonia: case series. Ann Rheum Dis. 2020; 79: 1381—2.

[134] Day JW, Fox TA, Halsey R, Carpenter B, Kottaridis PD. Interleukin—1 blockade with anakinra in acute leukaemia patients with severe COVID—19 pneumonia appears safe and may result in clinical improvement. Br J Haematol. 2020; 190: e80-3.

[135] Pontali E, Volpi S, Antonucci G, Castellaneta M, Buzzi D, Tricerri F, et al. Safety and efficacy of early high—dose IV anakinra in severe COVID—19 lung disease. J Allergy Clin Immunol. 2020; 146: 213—5.

[136] Navarro—Millán I, Sattui SE, Lakhanpal A, Zisa D, Siegel CH, Crow MK. Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID—19: A Case Series. Arthritis Rheumatol. 2020; 72: 1990—7.

[137] Nemchand P, Tahir H, Mediwake R, Lee J. Cytokine storm and use of anakinra in a patient with COVID—19. BMJ Case Rep. 2020; 13: e237525.

[138] Huet T, Beaussier H, Voisin O, Jouveshomme S, Dauriat G, Lazareth I, et al. Anakinra for severe forms of COVID—19: a cohort study. Lancet Rheumatol. 2020; 2: e393-400.

[139] De Luca G, Cavalli G, Campochiaro C, Della—Torre E, Angelillo P, Tomelleri A, et al. GM—CSF blockade with mavrilimumab in severe COVID—19 pneumonia and systemic hyperinflammation: a single—centre, prospective cohort study. Lancet Rheumatol. 2020; 2: e465-73.

[140] Cremer PC, Abbate A, Hudock K, McWilliams C, Mehta J, Chang SY, et al. ; MASH—COVID study group. Mavrilimumab in patients with severe COVID—19 pneumonia and systemic hyperinflammation (MASH—COVID): an investigator initiated, multicentre, double—blind, randomised, placebo—controlled trial. Lancet Rheumatol. 2021; 3: e410—8.

[141] Diurno F, Numis FG, Porta G, Cirillo F, Maddaluno S, Ragozzino A, et al. Eculizumab treatment in patients with COVID—19: preliminary results from real life ASL Napoli 2 Nord experience. Eur Rev Med Pharmacol Sci. 2020; 24: 4040-7.

[142] Giudice V, Pagliano P, Vatrella A, Masullo A, Poto S, Polverino BM, et al. Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS—CoV—2—Related Acute Respiratory Distress Syndrome: A Controlled Study. Front Pharmacol. 2020; 11: 857.

[143] Laurence J, Mulvey JJ, Seshadri M, Racanelli A, Harp J, Schenck EJ, et al. Anti—complement C5 therapy with eculizumab in three cases of critical COVID—19. Clin Immunol. 2020; 219: 108555.

[144] Patterson BK, Seethamraju H, Dhody K, Corley MJ, Kazempour K, Lalezari J, et al. CCR5 inhibition in critical COVID—19 patients decreases inflammatory cytokines, increases CD8 T—cells, and decreases SARS—CoV2 RNA in plasma by day 14. Int J Infect Dis. 2021; 103: 25-32.

[145] Yang B, Fulcher JA, Ahn J, Berro M, Goodman—Meza D, Dhody K, et al. Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Patients Who Received Compassionate—Use Leronlimab. Clin Infect Dis. 2021; 73: e4082—9.

[146] Gupta A, Sharma YK, Deo K, Kothari P. Severe recalcitrant psoriasis treated with itolizumab, a novel anti—CD6 monoclonal antibody. Indian J Dermatol Venereol Leprol. 2016; 82: 459-61.

[147] Kumari P, Kumar A, Sinha C, Kumar A, Singh PK, Arun SK. Off—label Use of Itolizumab in Patients with COVID—19 ARDS: Our Clinical Experience in a Dedicated COVID Center. Indian J Crit Care Med. 2021; 25: 467—9.

[148] Chen CY, Chen WC, Hsu CK, Chao CM, Lai CC. Clinical efficacy and safety of Janus kinase inhibitors for COVID—19: A systematic review and meta—analysis of randomized controlled trials. Int Immunopharmacol. 2021; 99: 108027.

[149] Neubauer A, Wiesmann T, Vogelmeier CF, Mack E, Skevaki C, Gaik C, et al. Ruxolitinib for the treatment of SARS—CoV—2 induced acute respiratory distress syndrome (ARDS). Leukemia. 2020; 34: 2276—8.

[150] Vannucchi AM, Sordi B, Morettini A, Nozzoli C, Poggesi L, Pieralli F, et al. ; RUXO—COVID Study Group. Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID—19: a prospective observational study. Leukemia. 2021; 35: 1121-33.

[151] Cantini F, Niccoli L, Matarrese D, Nicastri E, Stobbione P, Goletti D. Baricitinib therapy in COVID—19: A pilot study on safety and clinical impact. J Infect. 2020; 81: 318-56.

[152] Agrawal M, Brenner EJ, Zhang X, Modesto I, Woolcott J, Ungaro RC, et al. Characteristics and Outcomes of IBD Patients with COVID—19 on Tofacitinib Therapy in the SECURE—IBD Registry. Inflamm Bowel Dis. 2021; 27: 585-9.

[153] Hayek ME, Mansour M, Ndetan H, Burkes Q, Corkern R, Dulli A, et al. Anti—Inflammatory Treatment of COVID—19 Pneumonia With Tofacitinib Alone or in Combination With Dexamethasone is Safe and Possibly Superior to Dexamethasone as a Single Agent in a Predominantly African American Cohort. Mayo Clin Proc Innov Qual Outcomes. 2021; 5: 605-13.

[154] Florescu DF, Kalil AC. Janus Kinase inhibitors for the treatment of hospitalized patients with COVID—19. Curr Opin Crit Care. 2021; 27: 493-6.

[155] Praveen D, Puvvada RC, M VA. Janus kinase inhibitor baricitinib is not an ideal option for management of COVID—19. Int J Antimicrob Agents. 2020; 55: 105967.

[156] Welsch K, Holstein J, Laurence A, Ghoreschi K. Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors. Eur J Immunol. 2017; 47: 1096-107.

[157] Mease P, Hall S, FitzGerald O, van der Heijde D, Merola JF, Avila—Zapata F, et al. Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis. N Engl J Med. 2017; 377: 1537—50.

[158] Papp KA, Menter MA, Abe M, Elewski B, Feldman SR, Gottlieb AB, et al. ; OPT Pivotal 1 and OPT Pivotal 2 investigators. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo—controlled, phase III trials. Br J Dermatol. 2015; 173: 949-61.

[159] Sisk JM, Frieman MB, Machamer CE. Coronavirus S protein—induced fusion is blocked prior to hemifusion by Abl kinase inhibitors. J Gen Virol. 2018; 99: 619—30.

[160] Coleman CM, Sisk JM, Mingo RM, Nelson EA, White JM, Frieman MB. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion. J Virol. 2016; 90: 8924—33.

[161] Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J, et al. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014; 58: 4885-93.

[162] Morales—Ortega A, Bernal—Bello D, Llarena—Barroso C, Frutos—Pérez B, Duarte—Millán MÁ, García de Viedma—García V, et al. Imatinib for COVID—19: A case report. Clin Immunol. 2020; 218: 108518.

[163] Weber ANR, Bittner Z, Liu X, Dang TM, Radsak MP, Brunner C. Bruton’s Tyrosine Kinase: An Emerging Key Player in Innate Immunity. Front Immunol. 2017; 8: 1454.

[164] Roschewski M, Lionakis MS, Sharman JP, Roswarski J, Goy A, Monticelli MA, et al. Inhibition of Bruton tyrosine kinase in patients with severe COVID—19. Sci Immunol. 2020; 5: eabd0110.

[165] Fiorcari S, Atene CG, Maffei R, Debbia G, Potenza L, Luppi M, et al. Ibrutinib interferes with innate immunity in chronic lymphocytic leukemia patients during COVID—19 infection. Haematologica. 2021; 106: 2265—8.

[166] Treon SP, Castillo JJ, Skarbnik AP, Soumerai JD, Ghobrial IM, Guerrera ML, et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID—19—infected patients. Blood. 2020; 135: 1912—5.

[167] Scarfò L, Chatzikonstantinou T, Rigolin GM, Quaresmini G, Motta M, Vitale C, et al. COVID—19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia. 2020; 34: 2354-63.

[168] Hahn KA, Ogilvie G, Rusk T, Devauchelle P, Leblanc A, Legendre A, et al. Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med. 2008; 22: 1301—9.

[169] Drayman N, DeMarco JK, Jones KA, Azizi SA, Froggatt HM, Tan K, et al. Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS—CoV—2. Science. 2021; 373: 931-6.

[170] Martínez—Ortega U, Figueroa—Figueroa DI, Hernández—Luis F, Aguayo—Ortiz R. In Silico Characterization of Masitinib Interaction with SARS—CoV—2 Main Protease. ChemMedChem. 2021; 16: 2339-44.

[171] Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 3) [Internet]. [cited 2020 Jan 23]. Available from: http://www.nhc.gov.cn/yzygj/s7653p/202001/f492c9153ea9437bb587ce2ffcbee1fa/files/39e7578d85964dbe81117736dd789d8f.pdf

[172] Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 8 Revised Edition) [Internet]. [cited 2021 Apr 15]. Available from: http://www.nhc.gov.cn/yzygj/s7653p/202104/7de0b3837c8b4606a0594aeb0105232b/files/f192ac6e5567469db4f0a8691ca18907.pdf

[173] Ding Y, Zeng L, Li R, Chen Q, Zhou B, Chen Q, et al. The Chinese prescription lianhuaqingwen capsule exerts anti—influenza activity through the inhibition of viral propagation and impacts immune function. BMC Complement Altern Med. 2017; 17: 130.

[174] Li R, Hong Y, Huang J, Pan W, Ma Q, Shi Y, et al. Lianhuaqingwen exerts anti—viral and anti—inflammatory activity against novel coronavirus (SARS—CoV—2). Pharmacol Res. 2020; 156: 104761.

[175] Hu K, Guan WJ, Bi Y, Zhang W, Li L, Zhang B, et al. Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial. Phytomedicine. 2021; 85: 153242.

[176] Jin YH, Zhan QY, Peng ZY, Ren XQ, Yin XT, Cai L, et al. ; Evidence—Based Medicine Chapter of China International Exchange and Promotive Association for Medical and Health Care (CPAM); Chinese Research Hospital Association (CRHA). Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID—19: An evidence—based clinical practice guideline (updated version). Mil Med Res. 2020; 7: 41.

[177] Tao Z, Yang Y, Shi W, Xue M, Yang W, Song Z, et al. Complementary and alternative medicine is expected to make greater contribution in controlling the prevalence of influenza. Biosci Trends. 2013; 7: 253-6.

[178] Liu Z, Li X, Gou C, Li L, Luo X, Zhang C, et al. Effect of Jinhua Qinggan granules on novel coronavirus pneumonia in patients. J Tradit Chin Med. 2020; 40: 467—72.

[179] 上海药物所、 武汉病毒所 初步发现中成药双黄连口服液可抑制新型冠状病毒 [Internet]. Beijing: Chinese Academy of Sciences; c1996—2025 [cited 2022 Mar 21]. Available from: http://www.cas.cn/yw/202001/t20200131_4733137.shtml

[180] Ni L, Zhou L, Zhou M, Zhao J, Wang DW. Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID—19. Front Med. 2020; 14: 210—4.

[181] Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends. 2020; 14: 64-8.

[182] Ma Q, Qiu M, Zhou H, Chen J, Yang X, Deng Z, et al. The study on the treatment of Xuebijing injection (XBJ) in adults with severe or critical Corona Virus Disease 2019 and the inhibitory effect of XBJ against SARS—CoV—2. Pharmacol Res. 2020; 160: 105073.

[183] Guo H, Zheng J, Huang G, Xiang Y, Lang C, Li B, et al. Xuebijing injection in the treatment of COVID—19: a retrospective case—control study. Ann Palliat Med. 2020; 9: 3235-48.

[184] Song Y, Yao C, Yao Y, Han H, Zhao X, Yu K, et al. XueBiJing Injection Versus Placebo for Critically Ill Patients With Severe Community—Acquired Pneumonia: A Randomized Controlled Trial. Crit Care Med. 2019; 47: e735—43.

[185] Yu S, Chen Y, Xiang Y, Lin H, Wang M, Ye W, et al. Pseudoephedrine and its derivatives antagonize wild and mutated severe acute respiratory syndrome—CoV—2 viruses through blocking virus invasion and antiinflammatory effect. Phytother Res. 2021; 35: 5847-60.

[186] Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 4) [Internet]. [cited 2020 Jan 27]. Available from: http://www.nhc.gov.cn/yzygj/s7653p/202001/4294563ed35b43209b31739bd0785e67/files/7a9309111267475a99d4306962c8bf78.pdf

[187] Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID—19 patients. Proc Natl Acad Sci U S A. 2020; 117: 9490—6.

[188] Liu STH, Lin HM, Baine I, Wajnberg A, Gumprecht JP, Rahman F, et al. Convalescent plasma treatment of severe COVID—19: a propensity score—matched control study. Nat Med. 2020; 26: 1708-13.

[189] Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life—threatening COVID—19: A Randomized Clinical Trial. JAMA. 2020; 324: 460-70.

[190] Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B, Winters JL, et al. Deployment of convalescent plasma for the prevention and treatment of COVID—19. J Clin Invest. 2020; 130: 2757-65.

[191] Corti D, Misasi J, Mulangu S, Stanley DA, Kanekiyo M, Wollen S, et al. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science. 2016; 351: 1339—42.

[192] Hoenen T, Groseth A, Feldmann H. Therapeutic strategies to target the Ebola virus life cycle. Nat Rev Microbiol. 2019; 17: 593-606.

[193] Yu F, Xiang R, Deng X, Wang L, Yu Z, Tian S, et al. Receptor—binding domain—specific human neutralizing monoclonal antibodies against SARS—CoV and SARS—CoV—2. Signal Transduct Target Ther. 2020; 5: 212.

[194] Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, et al. Human neutralizing antibodies elicited by SARS—CoV—2 infection. Nature. 2020; 584: 115-9.

[195] Wu Y, Wang F, Shen C, Peng W, Li D, Zhao C, et al. A noncompeting pair of human neutralizing antibodies block COVID—19 virus binding to its receptor ACE2. Science. 2020; 368: 1274—8.

[196] Cao Y, Su B, Guo X, Sun W, Deng Y, Bao L, et al. Potent Neutralizing Antibodies against SARS—CoV—2 Identified by High—Throughput Single—Cell Sequencing of Convalescent Patients’ B Cells. Cell. 2020; 182: 73-84.e16.

[197] Hurlburt NK, Seydoux E, Wan YH, Edara VV, Stuart AB, Feng J, et al. Structural basis for potent neutralization of SARS—CoV—2 and role of antibody affinity maturation. Nat Commun. 2020; 11: 5413.

[198] Zhou D, Duyvesteyn HME, Chen CP, Huang CG, Chen TH, Shih SR, et al. Structural basis for the neutralization of SARS—CoV—2 by an antibody from a convalescent patient. Nat Struct Mol Biol. 2020; 27: 950-8.

[199] Wrapp D, De Vlieger D, Corbett KS, Torres GM, Wang N, Van Breedam W, et al.; VIB—CMB COVID—19 Response Team; Hoffmann M, Pöhlmann S, Graham BS, Callewaert N, Schepens B, Saelens X, et al. Structural Basis for Potent Neutralization of Betacoronaviruses by Single—Domain Camelid Antibodies. Cell. 2020; 181: 1004-15.e15.

[200] Pinto D, Park YJ, Beltramello M, Walls AC, Tortorici MA, Bianchi S, et al. Cross—neutralization of SARS—CoV—2 by a human monoclonal SARS—CoV antibody. Nature. 2020; 583: 290-5.

[201] Chi X, Yan R, Zhang J, Zhang G, Zhang Y, Hao M, et al. A neutralizing human antibody binds to the N—terminal domain of the Spike protein of SARS—CoV—2. Science. 2020; 369: 650-5.

[202] Barnes CO, West AP Jr, Huey—Tubman KE, Hoffmann MAG, Sharaf NG, Hoffman PR, et al. Structures of Human Antibodies Bound to SARS—CoV—2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. Cell. 2020; 182: 828-42.e16.

[203] Jones BE, Brown—Augsburger PL, Corbett KS, Westendorf K, Davies J, Cujec TP, et al. The neutralizing antibody, LY—CoV555, protects against SARS—CoV—2 infection in nonhuman primates. Sci Transl Med. 2021; 13: eabf1906.

[204] Hansen J, Baum A, Pascal KE, Russo V, Giordano S, Wloga E, et al. Studies in humanized mice and convalescent humans yield a SARS—CoV—2 antibody cocktail. Science. 2020; 369: 1010-4.

[205] Wang R, Zhang Q, Ge J, Ren W, Zhang R, Lan J, et al. SARS—CoV—2 variants resist antibody neutralization and broaden host ACE2 usage. bioRxiv 2021.03.09.434497 [Preprint]. 2021 [cited 2022 Mar 21]. Available from: https://doi.org/10.1101/2021.03.09.434497

[206] Zhang Y, Hao X, Ma J, Wang M, Li Y, Liu Y, et al. Phase 1 Safety and Pharmacokinetics Studies of BRII—196 and BRII—198, SARS—CoV—2 Spike—Targeting Monoclonal Antibodies. medRxiv 2021.07.21.21260964 [Preprint]. 2021 [cited 2022 Mar 21]: [25 p.]. Available from: https://doi.org/10.1101/2021.07.21.21260964

[207] Monteil V, Kwon H, Prado P, Hagelkrüys A, Wimmer RA, Stahl M, et al. Inhibition of SARS—CoV—2 Infections in Engineered Human Tissues Using Clinical—Grade Soluble Human ACE2. Cell. 2020; 181: 905—13.e7.

[208] Zoufaly A, Poglitsch M, Aberle JH, Hoepler W, Seitz T, Traugott M, et al. Human recombinant soluble ACE2 in severe COVID—19. Lancet Respir Med. 2020; 8: 1154— 8.

[209] Zhang G, Pomplun S, Loftis AR, Tan X, Loas A, Pentelute BL. Investigation of ACE2 N—terminal fragments binding to SARS—CoV—2 Spike RBD. bioRxiv 2020.03.19.999318 [Preprint]. 2020 [cited 2022 Mar 21]. Available from: https://doi.org/10.1101/2020.03.19.999318

[210] WHO COVID—19 dashboard [Internet]. WHO; c2024 [cited 2022 Jun 20]. Available from: https://covid19.who.int/

[211] Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type—5 vectored COVID—19 vaccine: a dose—escalation, open—label, non—randomised, first—in—human trial. Lancet. 2020; 395: 1845-54.

[212] Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. ; mRNA—1273 Study Group. An mRNA Vaccine against SARS—CoV—2 — Preliminary Report. N Engl J Med. 2020; 383: 1920—31.

[213] Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. ; COVE Study Group. Efficacy and Safety of the mRNA—1273 SARS—CoV—2 Vaccine. N Engl J Med. 2021; 384: 403—16.

[214] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. ; C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid—19 Vaccine. N Engl J Med. 2020; 383: 2603—15.

[215] COVID—19 vaccine tracker and landscape [Internet]. WHO; c2025 [cited 2022 Jun 21]. Available from: https://www.who.int/publications/m/item/draft—landscape—of—covid—19—candidate—vaccines

[216] Wang K, Long QX, Deng HJ, Hu J, Gao QZ, Zhang GJ, et al. Longitudinal Dynamics of the Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS—CoV—2) Infection. Clin Infect Dis. 2021; 73: e531-9.

[217] Carr AC, Rosengrave PC, Bayer S, Chambers S, Mehrtens J, Shaw GM. Hypovitaminosis C and vitamin C deficiency in critically ill patients despite recommended enteral and parenteral intakes. Crit Care. 2017; 21: 300.

[218] Chiscano—Camón L, Ruiz—Rodriguez JC, Ruiz—Sanmartin A, Roca O, Ferrer R. Vitamin C levels in patients with SARS—CoV—2—associated acute respiratory distress syndrome. Crit Care. 2020; 24: 522.

[219] Arvinte C, Singh M, Marik PE. Serum Levels of Vitamin C and Vitamin D in a Cohort of Critically Ill COVID—19 Patients of a North American Community Hospital Intensive Care Unit in May 2020: A Pilot Study. Med Drug Discov. 2020; 8: 100064.

[220] Hiedra R, Lo KB, Elbashabsheh M, Gul F, Wright RM, Albano J, et al. The use of IV vitamin C for patients with COVID—19: a case series. Expert Rev Anti Infect Ther. 2020; 18: 1259-61.

[221] Fontana F, Cazzato S, Giovanella S, Ballestri M, Leonelli M, Mori G, et al. Oxalate Nephropathy Caused by Excessive Vitamin C Administration in 2 Patients With COVID—19. Kidney Int Rep. 2020; 5: 1815-22.

[222] Christakos S, Li S, De La Cruz J, Bikle DD. New developments in our understanding of vitamin metabolism, action and treatment. Metabolism. 2019; 98: 112-20.

[223] Grant WB, Lahore H, McDonnell SL, Baggerly CA, French CB, Aliano JL, et al. Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID—19 Infections and Deaths. Nutrients. 2020; 12: 988.

[224] Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, et al. Toll—like receptor triggering of a vitamin D—mediated human antimicrobial response. Science. 2006; 311: 1770—3.

[225] Adams JS, Ren S, Liu PT, Chun RF, Lagishetty V, Gombart AF, et al. Vitamin D—directed rheostatic regulation of monocyte antibacterial responses. J Immunol. 2009; 182: 4289-95.

[226] Grant WB, Giovannucci E. The possible roles of solar ultraviolet—B radiation and vitamin D in reducing case—fatality rates from the 1918—1919 influenza pandemic in the United States. Dermatoendocrinol. 2009; 1: 215—9.

[227] D’Avolio A, Avataneo V, Manca A, Cusato J, De Nicolò A, Lucchini R, et al. 25—Hydroxyvitamin D Concentrations Are Lower in Patients with Positive PCR for SARS—CoV—2. Nutrients. 2020; 12: 1359.

[228] Kara M, Ekiz T, Ricci V, Kara Ö, Chang KV, Özçakar L. ‘Scientific Strabismus’ or two related pandemics: coronavirus disease and vitamin D deficiency. Br J Nutr. 2020; 124: 736—41.

[229] Rhodes JM, Subramanian S, Laird E, Kenny RA. Editorial: low population mortality from COVID—19 in countries south of latitude 35 degrees North supports vitamin D as a factor determining severity. Aliment Pharmacol Ther. 2020; 51: 1434-7.

[230] Ilie PC, Stefanescu S, Smith L. The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality. Aging Clin Exp Res. 2020; 32: 1195—8.

[231] Balfour JA, Wiseman LR. Moxifloxacin. Drugs. 1999; 57: 363-73.

[232] LiverTox: Clinical and Research Information on Drug—Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012.

[233] Touret F, Gilles M, Barral K, Nougairède A, van Helden J, Decroly E, et al. In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS—CoV—2 replication. Sci Rep. 2020; 10: 13093.

[234] Andreani J, Le Bideau M, Duflot I, Jardot P, Rolland C, Boxberger M, et al. In vitro testing of combined hydroxychloroquine and azithromycin on SARS—CoV—2 shows synergistic effect. Microb Pathog. 2020; 145: 104228.

[235] Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Sevestre J, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID—19 patients with at least a six—day follow up: A pilot observational study. Travel Med Infect Dis. 2020; 34: 101663.

[236] Tian S, Zhang J, Yuan S, Wang Q, Lv C, Wang J, et al. Exploring pharmacological active ingredients of traditional Chinese medicine by pharmacotranscriptomic map in ITCM. Brief Bioinform. 2023; 24: bbad027.

[237] Tian S, Li Y, Xu J, Zhang L, Zhang J, Lu J, et al. COIMMR: a computational framework to reveal the contribution of herbal ingredients against human cancer via immune microenvironment and metabolic reprogramming. Brief Bioinform. 2023; 24: bbad346.

[238] Xu HY, Zhang YQ, Liu ZM, Chen T, Lv CY, Tang SH, et al. ETCM: an encyclopaedia of traditional Chinese medicine. Nucleic Acids Res. 2019; 47: D976-82.